Overview

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Status:
Completed
Trial end date:
2019-12-23
Target enrollment:
Participant gender:
Summary
A Randomized,Open-label, Single-Dose,Two-Cycle,Cross- Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers.
Phase:
N/A
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Doxorubicin
Liposomal doxorubicin